Skip to main content

Newsroom

Press Releases

December 12, 2017
Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations GAITHERSBURG, Md., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 milli...

 


Corporate Headquarters Ribbon Cutting

Media
Lynn R. Kieffer
kiefferl@ebsi.com 
TEL 240-631-3391 

Investors
Robert Burrows 
burrowsr@ebsi.com 
TEL 240-631-3280